

REQUEST FOR RECONSIDERATION

Applicants thank Examiner Wu for the indication that the subject matter of Claim 4 is allowable if rewritten in independent form. Claim 4 has been rewritten in independent form.


The Office rejected Claims 1 and 5 under 35 U.S.C. § 112, first paragraph, alleging that the specification is not enabling for the connection of an isoleucine derivative and a carbazolyl derivative. Applicants traverse the rejection on the grounds that the Office has provided no reasonable technical basis to support the rejection. The Office's rejection appears to constitute no more than the Office's opinion with regards to the connectivity between isoleucine and carbozolyl groups. In the absence of a reasonable technical basis for the rejection, Applicants submit that the rejection is improper and should be withdrawn.

The Office further rejected Claims 1-3 and 5 under 35 U.S.C. § 112, second paragraph for indefiniteness. The Office asserts that the terms isoleucine derivative and carbazolyl are "too broadly claimed". Applicants wish to note that breadth is not indefiniteness. In this regard, Applicants draw the Office's attention to M.P.E.P. § 2173.04 - Breadth is Not Indefiniteness.

Applicants submit that all now-pending claims are in condition for allowance. Applicants respectfully request allowance of all now-pending claims.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Stefan U. Koschmieder, Ph.D.  
Registration No. 50,238

Customer Number

22850

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)

NFO:SUK\la